Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record.

Prognostic Value of Ishak Fibrosis Stage: Findings From the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial

Open access
Everhart, James E., Wright, Elizabeth C., Goodman, Zachary D., Dienstag, Jules L., Hoefs, John C., Kleiner, David E., Ghany, Marc G., Mills, Scott A., Nash, Russell S., Govindarajan, Sugantha, Rogers, Thomas E., Greenson, Joel K., Brunt, Elizabeth M., Bonkovsky, Herbert L., Morishima, Chihiro, Litman, Heather J.·2010·Hepatology

Abstract

Studies of the prognostic value of Ishak fibrosis stage are lacking. We used multi-year follow-up of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial to determine whether individual Ishak fibrosis stages predicted clinical outcomes in patients with chronic hepatitis C. Baseline liver biopsy specimens from 1050 patients with compensated chronic hepatitis C who had failed combination peginterferon and ribavirin were reviewed by a panel of expert hepatopathologists. Fibrosis was staged with the Ishak scale (ranging from 0 = no fibrosis to 6 = cirrhosis). Biopsy fragmentation and length as well as number of portal tracts were recorded. We compared rates of prespecified clinical outcomes of hepatic decompensation and hepatocellular carcinoma across individual Ishak fibrosis stages. Of 1050 biopsy specimens, 25% were fragmented, 63% longer than 1.5 cm, 69% larger than 10 mm2, and 75% had 10 or more portal tracts. Baseline laboratory markers of liver disease severity were worse and the frequency of esophageal varices higher with increasing Ishak stage ( P < 0.0001). The 6-year cumulative incidence of first clinical outcome was 5.6% for stage 2, 16.1% for stage 3, 19.3% for stage 4, 37.8% for stage 5, and 49.3% for stage 6. Among nonfragmented biopsy specimens, the predictive ability of Ishak staging was enhanced; however, no association was observed between Ishak stage and outcomes for fragmented biopsy specimens because of high rates of outcomes for patients with noncirrhotic stages. Similar results were observed with liver transplantation or liver-related death as the outcome. Conclusion : Ishak fibrosis stage predicts clinical outcomes, need for liver transplantation, and liver-related death in patients with chronic hepatitis C. Patients with fragmented biopsy specimens with low Ishak stage may be understaged histologically. (Hepatology 2010;51:585–594.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.23315

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 208

Metadata

Authors
Everhart, J. E., Wright, E. C., Goodman, Z. D., Dienstag, J. L., Hoefs, J. C., Kleiner, D. E., Ghany, M. G., Mills, S. A., Nash, R. S., Govindarajan, S., Rogers, T. E., Greenson, J. K., Brunt, E. M., Bonkovsky, H. L., Morishima, C., & Litman, H. J.
Venue
Hepatology
Published
2010-02
Volume
51
Issue
2
Pages
585-594
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2056460716
Cited by
208
References
0
FWCI
4.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Value of Ishak Fibrosis Stage: Findings From the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. https://app.cochat.ai/papers/10.1002/hep.23315
The paper
Everhart, J. E., Wright, E. C., Goodman, Z. D., Dienstag, J. L., Hoefs, J. C., Kleiner, D. E., Ghany, M. G., Mills, S. A., Nash, R. S., Govindarajan, S., Rogers, T. E., Greenson, J. K., Brunt, E. M., Bonkovsky, H. L., Morishima, C., & Litman, H. J. (2010). Prognostic Value of Ishak Fibrosis Stage: Findings From the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Hepatology. https://doi.org/10.1002/hep.23315

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.